Abstract:The majority of therapies that target individual proteins rely on specific activity-modulating interactions with the target protein—for example, enzyme inhibition or ligand blocking. However, several major classes of therapeutically relevant proteins have unknown or inaccessible activity profiles and so cannot be targeted by such strategies. Protein-degradation platforms such as proteolysis-targeting chimaeras (PROTACs)<a href="/articles/s41586-020-2545-9#ref-CR1">1</a>,<a href="/articles/s41586-020-2545-9#ref-CR2">2</a> and others (for example, dTAGs<a href="/articles/s41586-020-2545-9#ref-CR3">3</a>, Trim-Away<a href="/articles/s41586-020-2545-9#ref-CR4">4</a>, chaperone-mediated autophagy targeting<a href="/articles/s41586-020-2545-9#ref-CR5">5</a> and SNIPERs<a href="/articles/s41586-020-2545-9#ref-CR6">6</a>) have been developed for proteins that are typically difficult to target; however, these methods involve the manipulation of intracellular protein degradation machinery and are therefore fundamentally limited to proteins that contain cytosolic domains to which ligands can bind and recruit the requisite cellular components. Extracellular and membrane-associated proteins—the products of 40% of all protein-encoding genes<a href="/articles/s41586-020-2545-9#ref-CR7">7</a>—are key agents in cancer, ageing-related diseases and autoimmune disorders<a href="/articles/s41586-020-2545-9#ref-CR8">8</a>, and so a general strategy to selectively degrade these proteins has the potential to improve human health. Here we establish the targeted degradation of extracellular and membrane-associated proteins using conjugates that bind both a cell-surface lysosome-shuttling receptor and the extracellular domain of a target protein. These initial lysosome-targeting chimaeras, which we term LYTACs, consist of a small molecule or antibody fused to chemically synthesized glycopeptide ligands that are agonists of the cation-independent mannose-6-phosphate receptor (CI-M6PR). We use LYTACs to develop a CRISPR interference screen that reveals the biochemical pathway for CI-M6PR-mediated cargo internalization in cell lines, and uncover the exocyst complex as a previously unidentified—but essential—component of this pathway. We demonstrate the scope of this platform through the degradation of therapeutically relevant proteins, including apolipoprotein E4, epidermal growth factor receptor, CD71 and programmed death-ligand 1. Our results establish a modular strategy for directing secreted and membrane proteins for lysosomal degradation, with broad implications for biochemical research and for therapeutics.

Multiple Look Angle Sar Recognition

An Engineered IGF2 Mutant for Lysosomal Targeting Chimeras Development and Membrane Proteins Degradation

Directed evolution of genetically encoded LYTACs for cell-mediated delivery

Applying the Query Change Retrieval Model on Session Search-Georgetown at TREC 2013 Session Track

Lysosome Targeting Chimeras (LYTACs) That Engage a Liver-Specific Asialoglycoprotein Receptor for Targeted Protein Degradation

Development of Integrin Targeting Chimeras (ITACs) for the Lysosomal Degradation of Extracellular Proteins

Lysosome-targeting chimaeras for degradation of extracellular proteins

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

Effects of ebelactone B, a lipase inhibitor, on intestinal fat absorption in the rat.

Peptide-Mediated Small Molecule Lysosome-Targeting Chimeras for Targeted Degradation of Membrane and Intracellular Proteins

Lysosome Targeting Chimaeras for Glut1-Facilitated Targeted Protein Degradation

Polymeric Lysosomal-Targeting Chimeras: Extracellular Targeted Protein Degradation Without Co-opting Lysosome-Targeting Receptors

Stereotypy of agonistic movements in the spider crab Microphrys bicornutus.

Effects of leukemia inhibitory factor (LIF) on gene transfer efficiency into murine hematolymphoid progenitors.

Lysosome-targeting chimeras containing an endocytic signaling motif trigger endocytosis and lysosomal degradation of cell-surface proteins

Targeted Protein Degradation Mediated by Genetically Engineered Lysosome-Targeting Exosomes

Multivalent Aptamer‐Based Lysosome‐Targeting Chimeras (LYTACs) Platform for Mono‐ or Dual‐Targeted Proteins Degradation on Cell Surface

Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor

Endosome-microautophagy targeting chimera (eMIATAC) for targeted proteins degradation and enhance CAR-T cell anti-tumor therapy

Engineering Antibody Fusion Proteins for Targeted Intracellular Therapeutic Delivery

LYMTACs: Chimeric Small Molecules Repurpose Lysosomal Membrane Proteins for Target Protein Relocalization and Degradation